12.3 Alzheimer's disease and other dementias
6 min read•august 15, 2024
and other dementias are devastating neurodegenerative disorders that affect millions worldwide. These conditions progressively impair memory, thinking, and behavior, ultimately interfering with daily life and independence.
Understanding the causes, symptoms, and management of dementias is crucial for improving patient care and developing new treatments. This section explores the clinical features, neuropathology, risk factors, and current approaches to managing these complex brain disorders.
Alzheimer's Disease: Clinical Features and Diagnosis
Characteristics and Progression of Alzheimer's Disease
Top images from around the web for Characteristics and Progression of Alzheimer's Disease
Frontiers | Nerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease View original
Is this image relevant?
2.4 Chronic Neurodegenerative Diseases – Neuroscience: Canadian 1st Edition View original
Is this image relevant?
Frontiers | Systems Biology Approaches to Understand the Host–Microbiome Interactions in ... View original
Is this image relevant?
Frontiers | Nerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease View original
Is this image relevant?
2.4 Chronic Neurodegenerative Diseases – Neuroscience: Canadian 1st Edition View original
Is this image relevant?
1 of 3
Top images from around the web for Characteristics and Progression of Alzheimer's Disease
Frontiers | Nerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease View original
Is this image relevant?
2.4 Chronic Neurodegenerative Diseases – Neuroscience: Canadian 1st Edition View original
Is this image relevant?
Frontiers | Systems Biology Approaches to Understand the Host–Microbiome Interactions in ... View original
Is this image relevant?
Frontiers | Nerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease View original
Is this image relevant?
2.4 Chronic Neurodegenerative Diseases – Neuroscience: Canadian 1st Edition View original
Is this image relevant?
1 of 3
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by gradual decline in cognitive function, particularly memory, language, and executive function
- The clinical features of AD typically begin with mild memory impairment and progress to more severe cognitive deficits, functional impairment, and behavioral changes
Diagnostic Criteria for Alzheimer's Disease and Other Dementias
- The diagnostic criteria for AD include a gradual onset and progressive decline in cognitive function, with memory impairment as the most common initial symptom
- Other cognitive domains, such as language, executive function, and visuospatial abilities, are also affected as the disease progresses
- is the second most common type of dementia caused by cerebrovascular disease or injury (stroke or chronic cerebral hypoperfusion) and commonly includes executive dysfunction, slowed processing speed, and gait disturbances
- (LBD) is characterized by fluctuating cognitive impairment, visual hallucinations, parkinsonism (tremor, rigidity, and bradykinesia), and REM sleep behavior disorder
- (FTD) is a group of neurodegenerative disorders that primarily affect the frontal and temporal lobes of the brain, with clinical features varying depending on the specific subtype but commonly including changes in behavior, personality, and language, with relative preservation of memory in the early stages
- refers to the presence of multiple types of dementia pathology in the brain (AD and vascular dementia), with clinical features varying depending on the specific combination of pathologies present
Neuropathological Changes in Alzheimer's Disease
Amyloid Plaques and Beta-Amyloid Peptide
- are composed of aggregated beta-amyloid peptide (Aβ), which is derived from the cleavage of amyloid precursor protein (APP) by β- and γ-secretases
- The accumulation of Aβ in the brain is thought to trigger a cascade of events leading to neuronal dysfunction and death
- Aβ peptides can exist in different forms (soluble monomers, oligomers, and insoluble fibrils), with soluble Aβ oligomers considered the most neurotoxic form that impair synaptic function and plasticity
- The distribution of amyloid plaques in the brain follows a characteristic pattern, with early involvement of the neocortex and later spread to the hippocampus and other subcortical regions
Neurofibrillary Tangles and Tau Protein
- Neurofibrillary tangles (NFTs) are intracellular aggregates of hyperphosphorylated tau protein, a microtubule-associated protein that normally functions to stabilize microtubules in neurons
- In AD, tau becomes hyperphosphorylated and dissociates from microtubules, leading to the formation of paired helical filaments and NFTs
- The distribution of NFTs in the brain follows a characteristic pattern described by the Braak staging system, with early involvement of the entorhinal cortex and hippocampus, and later spread to the neocortex
- The accumulation of NFTs is associated with neuronal dysfunction and death, and the severity of cognitive impairment in AD correlates more closely with the burden of NFTs than with amyloid plaques
Other Neuropathological Changes
- Other neuropathological changes in AD include neuronal and synaptic loss, inflammation, and oxidative stress
- These changes are thought to contribute to the progressive and brain atrophy observed in AD
Risk Factors for Alzheimer's Disease and Dementia
Age and Genetic Factors
- is the greatest risk factor for developing AD and other dementias, with the incidence increasing exponentially after age 65, although AD is not a normal part of aging
- Genetic factors play a significant role in the risk of developing AD, with the ε4 allele of the apolipoprotein E (APOE) gene being the strongest known genetic risk factor for late-onset AD
- Rare autosomal dominant mutations in the APP, presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes cause early-onset familial AD, which accounts for less than 1% of all AD cases
- Genetic factors also influence the risk of developing other types of dementia (frontotemporal dementia and Lewy body dementia)
Lifestyle and Environmental Factors
- Cardiovascular risk factors (hypertension, diabetes, obesity, and smoking) are associated with an increased risk of developing AD and vascular dementia by contributing to cerebrovascular disease and reduced brain reserve
- Traumatic brain injury (TBI), particularly moderate to severe TBI, is associated with an increased risk of developing AD and other dementias later in life, possibly involving neuroinflammation, oxidative stress, and accelerated accumulation of AD pathology
- Low educational attainment and lack of cognitive stimulation throughout life are associated with an increased risk of developing AD and other dementias, while engaging in mentally stimulating activities (reading, puzzles, and social interaction) may help to build cognitive reserve and delay the onset of dementia symptoms
- Other potential risk factors for AD and other dementias include depression, social isolation, hearing loss, and sleep disturbances, although the causal relationships between these factors and dementia risk are not fully established
Managing Symptoms of Dementia
Pharmacological Interventions
- (AChEIs), such as donepezil, rivastigmine, and galantamine, are the primary pharmacological treatment for mild to moderate AD, working by increasing the levels of acetylcholine in the brain and providing modest improvements in cognitive function, daily functioning, and behavioral symptoms in some individuals with AD
- is an NMDA receptor antagonist approved for the treatment of moderate to severe AD, working by regulating glutamate activity and providing modest benefits in cognitive function, daily functioning, and behavioral symptoms in some individuals with AD, often used in combination with AChEIs in the later stages of AD
- Antipsychotic medications (risperidone and olanzapine) are sometimes used off-label to manage severe (BPSD), such as agitation, aggression, and psychosis, but are associated with significant risks (increased mortality) and should be used with caution and only after have been tried
Non-Pharmacological Interventions and Caregiver Support
- Non-pharmacological interventions, such as cognitive stimulation therapy (CST), reminiscence therapy, and music therapy, have been shown to provide benefits for individuals with dementia by engaging and stimulating cognitive function, improving mood and behavior, and enhancing quality of life
- CST involves engaging in mentally stimulating activities (puzzles, word games, and discussions) in a group setting and has been shown to improve cognitive function and quality of life in individuals with mild to moderate dementia
- Reminiscence therapy involves discussing and sharing memories from the past, often using prompts (photographs or music), and has been shown to improve mood, communication, and sense of identity in individuals with dementia
- Music therapy involves listening to or creating music and has been shown to reduce anxiety, agitation, and depression in individuals with dementia, and may also help to stimulate memories and enhance social interaction
- Caregiver support interventions (education, skills training, and support groups) are essential for managing the challenges of caring for an individual with dementia and can help caregivers to better understand the disease process, develop effective communication and problem-solving strategies, and reduce and stress
- Respite care services (adult day care or in-home care) can provide temporary relief for caregivers and allow them to attend to their own needs and well-being
- Advance care planning, including discussions about end-of-life preferences and legal and financial matters, is an important aspect of supporting individuals with dementia and their caregivers, helping to ensure that the individual's wishes are respected and reducing stress and uncertainty for caregivers
Key Terms to Review (24)
Acetylcholinesterase inhibitors: Acetylcholinesterase inhibitors are a class of drugs that block the action of the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine in the brain. By preventing the breakdown of acetylcholine, these inhibitors increase its availability and enhance cholinergic neurotransmission, which can be particularly beneficial in conditions characterized by cognitive decline, such as Alzheimer's disease and other dementias.
Activities of daily living: Activities of daily living (ADLs) refer to the basic tasks essential for self-care and daily functioning, such as bathing, dressing, eating, toileting, and mobility. These activities are crucial indicators of a person's functional status and independence. The ability to perform ADLs can be significantly impacted by various neurological conditions, which can lead to a decline in cognitive and motor skills.
Age: Age refers to the length of time that a person has lived or a thing has existed. In the context of cognitive health and conditions like Alzheimer's disease and other dementias, age is a significant risk factor that influences the likelihood of developing these disorders, with older adults being at a higher risk due to biological and environmental changes associated with aging.
Alzheimer's disease: Alzheimer's disease is a progressive neurodegenerative disorder characterized by the gradual decline in cognitive function, memory, and the ability to perform daily activities. It leads to structural brain changes, including the accumulation of amyloid plaques and tau tangles, impacting communication, attention, and overall brain health.
Amyloid plaques: Amyloid plaques are abnormal clusters of protein fragments that accumulate between nerve cells in the brain, primarily composed of beta-amyloid peptides. These plaques are a hallmark feature of Alzheimer's disease and are believed to disrupt cell communication, trigger inflammation, and lead to the death of neurons, contributing to cognitive decline and dementia.
Behavioral and psychological symptoms of dementia: Behavioral and psychological symptoms of dementia (BPSD) refer to a range of non-cognitive disturbances that can occur in individuals with dementia. These symptoms can include changes in mood, behavior, and personality, often manifesting as agitation, depression, anxiety, hallucinations, or delusions. Understanding BPSD is crucial as they significantly impact the quality of life for both patients and caregivers and often require tailored interventions.
Biomarkers: Biomarkers are measurable indicators of a biological state or condition, often used in medicine to assess health, disease progression, or response to treatment. In the context of neurodegenerative diseases like Alzheimer's, biomarkers can include specific proteins or genetic changes that signal the presence or advancement of the disease, aiding in early diagnosis and monitoring.
Caregiver burden: Caregiver burden refers to the physical, emotional, and psychological strain experienced by individuals who provide care for someone with a chronic illness or disability, such as those affected by Alzheimer's disease and other dementias. This burden often arises from the demands of caregiving, which can lead to stress, fatigue, and feelings of isolation. Understanding caregiver burden is crucial, as it impacts not only the caregivers but also the quality of care provided to those they support.
Cholinesterase inhibitors: Cholinesterase inhibitors are a class of medications that block the activity of the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine in the brain. By inhibiting this enzyme, these drugs increase the levels of acetylcholine, thereby enhancing cholinergic neurotransmission, which is particularly beneficial in conditions like Alzheimer's disease and other dementias characterized by cholinergic deficits.
Clinical trials: Clinical trials are research studies that test how well new medical approaches work in people. They play a crucial role in determining the safety and effectiveness of treatments for various conditions, including mental health disorders and neurodegenerative diseases. By systematically evaluating new interventions, clinical trials help advance medical knowledge and improve patient care in diverse areas of health.
Cognitive assessments: Cognitive assessments are standardized tests and evaluations designed to measure various cognitive abilities, including memory, attention, problem-solving, and reasoning. They play a crucial role in diagnosing conditions such as Alzheimer's disease and other dementias, as they help to identify specific cognitive deficits and track changes over time.
Cognitive decline: Cognitive decline refers to the gradual decrease in cognitive abilities such as memory, attention, and problem-solving skills that often occurs with aging or as a result of neurological conditions. This decline can significantly impact an individual's daily functioning and quality of life, particularly in relation to various types of dementias, including Alzheimer's disease, where the progression of cognitive impairment is a key characteristic.
Frontotemporal dementia: Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder that primarily affects the frontal and temporal lobes of the brain, leading to changes in personality, behavior, and language. This condition is particularly known for causing significant disruptions in executive functions and language abilities, making it distinct from other forms of dementia such as Alzheimer's disease. FTD can manifest through various symptoms, including social withdrawal, impulsivity, and difficulties in communication, emphasizing its impact on both cognitive and emotional aspects of functioning.
Genetic predisposition: Genetic predisposition refers to the increased likelihood of developing certain traits or disorders due to one's genetic makeup. This concept emphasizes how inherited genes can influence an individual's susceptibility to various mental health conditions and neurological disorders, interacting with environmental factors to shape overall health outcomes.
Lewy Body Dementia: Lewy Body Dementia is a progressive neurological disorder characterized by the presence of abnormal protein deposits called Lewy bodies in the brain. These deposits disrupt normal brain function, leading to symptoms such as cognitive decline, visual hallucinations, and fluctuations in attention and alertness. This type of dementia shares features with both Alzheimer’s disease and Parkinson’s disease, making it an important focus within the study of various dementias.
Memantine: Memantine is a medication primarily used to treat moderate to severe Alzheimer's disease by acting as an N-methyl-D-aspartate (NMDA) receptor antagonist. By blocking the effects of excess glutamate, which can lead to neurotoxicity and cognitive decline, memantine helps improve memory, attention, and overall cognitive function in patients with dementia.
Memory loss: Memory loss refers to the inability to recall or recognize past experiences, information, or skills, which can significantly impact daily functioning. It is often a primary symptom of various neurological conditions, most notably Alzheimer's disease and other dementias, leading to challenges in personal relationships and independence as cognitive abilities decline.
Mild cognitive impairment: Mild cognitive impairment (MCI) is a condition characterized by noticeable cognitive decline that is greater than expected for a person's age but does not interfere significantly with daily life. Individuals with MCI may experience problems with memory, attention, and language, making them more vulnerable to developing more serious forms of dementia, including Alzheimer's disease.
Mixed dementia: Mixed dementia is a condition where a person exhibits symptoms of more than one type of dementia simultaneously, most commonly Alzheimer's disease and vascular dementia. This overlapping presentation can complicate diagnosis and treatment, as the cognitive decline may involve various pathways and mechanisms related to both forms of dementia, leading to a diverse range of symptoms.
Neuroimaging: Neuroimaging refers to a range of techniques used to visualize the structure and function of the brain. These methods allow researchers and clinicians to observe brain activity and identify abnormalities or changes in brain structure that are associated with various neurological conditions. By providing insights into how different areas of the brain are activated during tasks or how they are affected by diseases, neuroimaging plays a crucial role in understanding language disorders, consciousness, dementias, and movement disorders.
Non-pharmacological interventions: Non-pharmacological interventions are strategies that do not involve medication to manage symptoms and improve the quality of life for individuals, particularly those dealing with cognitive decline, such as in Alzheimer's disease and other dementias. These approaches can include lifestyle changes, therapeutic activities, and supportive environments that focus on enhancing cognitive function and emotional well-being. By emphasizing non-drug therapies, these interventions aim to address the holistic needs of patients while minimizing potential side effects associated with medications.
Severe dementia: Severe dementia is an advanced stage of cognitive decline characterized by significant impairment in memory, reasoning, and communication abilities, leading to a loss of independence and the inability to perform daily activities. Individuals with severe dementia often require full-time care and support, and this condition can be particularly prevalent in cases of Alzheimer's disease and other types of dementia.
Tau tangles: Tau tangles are abnormal aggregates of the protein tau that accumulate inside neurons and are considered a hallmark of neurodegenerative diseases, particularly Alzheimer's disease. These tangles disrupt neuronal function and contribute to cell death, leading to cognitive decline and memory loss. The presence of tau tangles is often correlated with the severity of dementia symptoms and the progression of neurodegenerative disorders.
Vascular dementia: Vascular dementia is a type of cognitive impairment caused by reduced blood flow to the brain, often resulting from strokes or other conditions that affect the vascular system. This condition can lead to difficulties with thinking, memory, and reasoning, and is often associated with other forms of dementia, including Alzheimer's disease. Understanding vascular dementia is crucial as it highlights the link between cardiovascular health and brain function.